Immune Effector Cell–associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report

IF 2.3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2026-06-26 Epub Date: 2026-09-14 DOI:10.1007/s00277-026-07105-x

Sofía Rincón-López, Ricardo García-Muñoz, Johelys Atencio-Matos, Olalla Pereda-Sainz, Javier Larreina-Pérez, Andrea Campeny-Najara, Pilar Herrera Pérez, Montserrat Hernández-Pérez, Jesús Feliu, Ada Esteban-Figuerola

{"title":"Immune Effector Cell–associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report","authors":"Sofía Rincón-López, Ricardo García-Muñoz, Johelys Atencio-Matos, Olalla Pereda-Sainz, Javier Larreina-Pérez, Andrea Campeny-Najara, Pilar Herrera Pérez, Montserrat Hernández-Pérez, Jesús Feliu, Ada Esteban-Figuerola","doi":"10.1007/s00277-026-07105-x","DOIUrl":null,"url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell–associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13572328/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-026-07105-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell–associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.

查看原文本刊更多论文

弥漫性大b细胞淋巴瘤（DLBCL） CAR-T治疗后，免疫效应细胞相关的噬血细胞综合征（IEC-HS）作为一种晚期免疫介导的毒性：一个病例报告

嵌合抗原受体（CAR） t细胞治疗可显著改善复发或难治性弥漫性大b细胞淋巴瘤（DLBCL）患者的预后[1,2]。然而，免疫介导的毒性是一个重要的新临床挑战，特别是那些迟发或不常见的表现。我们报告了一例71岁的女性重度预处理DLBCL患者，在CAR-T输注6个月后出现免疫效应细胞相关的噬血细胞综合征（IEC-HS），结果致命。该病例强调了晚发性CAR-T相关毒性的发生以及CAR-T细胞持久性在维持失调的免疫激活中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.